Keywords: strong, ph, ii, data, algeta, alpharadin, oslo

Strong Ph II data for Algeta's Alpharadin

Article | 13 March 2006

Print This

Oslo, Norway-based radionuclide cancer drug specialist Algeta has reported strong biomarker data from a Phase II trial of its lead ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in